NVCT (Nuvectis Pharma Inc.) stock: $22.00, $717.5M market cap, $22.2M cash, $695.3M EV, $728.0M fully diluted market cap. Next expected readout: Dec-26. Lead program: NXP900 (EGFR Mutation Positive Non-small Cell Lung Cancer), Phase 1. Data from Fully Diluted's biotech stocks database.
Balance sheet
| Cash | $22.2M |
|---|
| Debt | $0.0M |
|---|
| Net cash | $22.2M |
|---|
| Enterprise value | $695.3M |
|---|
| Basic shares | 26.7M shares |
|---|
| Fully diluted shares | 33.1M shares |
|---|
| Fully diluted market cap | $728.0M |
|---|
| Cash per share | $0.83 |
|---|
Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.
Price history
Loading NVCT daily closes…
Loading price history…
Upcoming catalysts
| Expected | Drug | Phase | Indication | Mgmt guide |
|---|
| Jan 12 - Feb 23 | NXP900 | Phase 1 | EGFR Mutation Positive Non-small Cell Lung Cancer; EGFR Mutated Non-small Cell Lung Cancer Patients | Q4 2026 |
| Apr 12 - May 24 | NXP900 | Phase 1 | Advanced Solid Tumor; NSCLC (Non-small Cell Lung Cancer); Renal Cancer | Q4 2026 |
| Sep 12 - Oct 24 | NXP900 | Phase 1 | ALK Positive; ALK Positive Non-small Cell Lung Cancer; NSCLC | Q4 2026 |
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Full readout calendar →
Pipeline assets
NXP100
Phase 3 · Active Modality: small molecule
Aliases HSK39297
Target Factor B (complement)
Partnerships Haisco Pharmaceutical Group Co: June 2026 license of exclusive worldwide (excluding China) development, manufacturing, and commercial rights (milestones + royalties on net sales)
Indications- IgA nephropathy (IgAN) (Phase 3)
- Lupus nephritis (LN) (Phase 2)
Status note Oral, once-daily, potent and selective small-molecule Factor B inhibitor for complement-related conditions. Phase 3 study for IgAN and Phase 2 study in LN ongoing in China; filing reports cross-trial activity similar to iptacopan with a similar safety profile.
NXP200
Stage not disclosed · Active Modality: small molecule
Aliases HSK42360
Target BRAF
Partnerships Haisco Pharmaceutical Group Co: June 2026 license of exclusive worldwide (excluding China) development, manufacturing, and commercial rights
Indications- Solid tumors (multiple) (Stage not disclosed)
- Primary brain cancer (Stage not disclosed)
Status note Paradox-breaker BRAF serine/threonine kinase inhibitor. Described in the filing as clinical-stage, but no trial phase is stated. Positioned for multiple solid tumor types and primary brain cancer, with potential to address resistance to first-generation BRAF inhibitors.
NXP900
Phase 1 · Active Modality: small molecule
Target YES1 / SRC kinases
Partnerships University of Edinburgh: exclusive license to composition-of-matter patent family (Aug 2021)
Status note Once-daily oral inhibitor of YES1 and SRC kinases. Phase 1a supported once-daily dosing; ongoing Phase 1b single-agent study in specific tumor types, Phase 1b combination with osimertinib (commenced December 2025), and a combination study with lorlatinib (ALK inhibitor) pending commencement.
NXP800
Phase 1 · Terminated
Partnerships CRT Pioneer Fund: worldwide exclusive license agreement (May 2021); milestones to ICR
Status note Following completion of the Phase 1b study in ovarian cancer (final clinical data update July 2025), the company decided to cease clinical development of NXP800 and is evaluating the feasibility of development in other cancer types.
Per-asset detail extracted from the 10-Q filed 2026-08-04. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.